SRPK1 has recently been suggested as a potential new molecular target that could be employed to facilitate the treatment of patients with early-stage gliomas, owing to its ability to regulate cell growth, metastasis, chemosensitivity and glioma angiogenesis (Sigala et al., 2016). The gene discussed is SRPK1; the disease is central nervous system cancer.